These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37147897)

  • 1. Population pharmacokinetic analysis of the P2X3-receptor antagonist gefapixant.
    Chawla A; Largajolli A; Hussain A; Kleijn H; Ait-Oudhia S; Anton J; Krishna Ananthula H; Nussbaum J; La Rosa C; Gheyas F
    CPT Pharmacometrics Syst Pharmacol; 2023 Aug; 12(8):1107-1118. PubMed ID: 37147897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist.
    Nussbaum JC; Hussain A; Min KC; Marbury TC; Lasseter K; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2022 Nov; 62(11):1435-1444. PubMed ID: 35656754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
    Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP;
    Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 3 Weeks of Orally Administered Gefapixant in Healthy Younger and Older Adults.
    Nussbaum J; Hussain A; Ford A; Butera P; Kitt M; Smith S; Stoch A; Iwamoto M
    Lung; 2022 Jun; 200(3):315-323. PubMed ID: 35670873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of gefapixant, a P2X
    McGarvey LP; Birring SS; Morice AH; Dicpinigaitis PV; Pavord ID; Schelfhout J; Nguyen AM; Li Q; Tzontcheva A; Iskold B; Green SA; Rosa C; Muccino DR; Smith JA;
    Lancet; 2022 Mar; 399(10328):909-923. PubMed ID: 35248186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.
    Smith JA; Birring SS; Dicpinigaitis PV; McGarvey LP; Morice AH; Pavord ID; Satia I; Green S; Iskold B; La Rosa C; Li Q; Martin Nguyen A; Schelfhout J; Muccino D
    Lung; 2022 Aug; 200(4):423-429. PubMed ID: 35895098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy Adults.
    Nussbaum JC; Hussain A; Butera P; Ford AP; Kitt MM; O'Neill EA; Smith S; Vargas G; O'Reilly T; Wynne C; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2024 Aug; 64(8):1023-1029. PubMed ID: 38651193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough.
    Niimi A; Sagara H; Kikuchi M; Arano I; Sato A; Shirakawa M; La Rosa C; Muccino D
    Allergol Int; 2022 Oct; 71(4):498-504. PubMed ID: 35752582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the Effect of Pyrimethamine, a Potent Inhibitor of Multidrug and Toxin Extrusion Protein 1/2K, on the Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist.
    Nussbaum JC; Hussain A; Ma B; Min KC; Evers R; Li Y; Garrett G; Stoch SA; Iwamoto M
    Clin Pharmacol Drug Dev; 2022 Jan; 11(1):123-128. PubMed ID: 34145987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Pharmacokinetic Interaction Between Gefapixant (MK-7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin.
    McCrea JB; Hussain A; Ma B; Garrett GC; Evers R; Laabs JE; Stoch SA; Iwamoto M
    Clin Pharmacol Drug Dev; 2022 Mar; 11(3):406-412. PubMed ID: 34821075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic Cough.
    Gupta P; Hussain A; Ford AP; Smith S; Nussbaum JC; Stoch A; Iwamoto M
    Clin Pharmacol Drug Dev; 2022 Sep; 11(9):1054-1067. PubMed ID: 35510785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough.
    McGarvey L; Sher M; Shvarts YG; Lu S; Wu WC; Xu P; Schelfhout J; La Rosa C; Nguyen AM; Reyfman PA; Afzal AS
    Lung; 2023 Apr; 201(2):111-118. PubMed ID: 36879087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans.
    Nussbaum JC; Hussain A; Ma B; Min KC; Chen Q; Tomek C; Iwamoto M; Stoch SA
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00924. PubMed ID: 35106949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial.
    Smith JA; Kitt MM; Bell A; Noulin N; Tzontcheva A; Seng MM; Lu S
    Pulm Ther; 2022 Sep; 8(3):297-310. PubMed ID: 35969360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefapixant in two randomised dose-escalation studies in chronic cough.
    Smith JA; Kitt MM; Butera P; Smith SA; Li Y; Xu ZJ; Holt K; Sen S; Sher MR; Ford AP
    Eur Respir J; 2020 Mar; 55(3):. PubMed ID: 31949115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
    Morice AH; Kitt MM; Ford AP; Tershakovec AM; Wu WC; Brindle K; Thompson R; Thackray-Nocera S; Wright C
    Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery and development of gefapixant.
    Ford AP; Dillon MP; Kitt MM; Gever JR
    Auton Neurosci; 2021 Nov; 235():102859. PubMed ID: 34403981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
    Muccino D; Green S
    Pulm Pharmacol Ther; 2019 Jun; 56():75-78. PubMed ID: 30880151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials.
    Chuang MH; Chen IW; Chen JY; Kang FC; Ho CN; Wu SC; Yew M; Lan KM; Hung KC
    Eur Respir Rev; 2023 Jun; 32(168):. PubMed ID: 37197770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefapixant: First Approval.
    Markham A
    Drugs; 2022 Apr; 82(6):691-695. PubMed ID: 35347635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.